-
Crizotinib, sold
under the
brand name
Xalkori among others, is an anti-cancer
medication used for the
treatment of non-small cell lung
carcinoma (NSCLC)...
-
implications on the
response of the
tumour and
prognosis of the patient.
Crizotinib (also a ROS1 and c-MET inhibitor) was
approved in Aug 2011 by the US FDA...
-
positive non-small cell lung cancer.
Treatment with
crizotinib achieves 60%
response rate. However,
crizotinib showed no
improvement on
overall survival compared...
-
metastatic non-small cell lung
cancer whose disease has
progressed on
crizotinib and at
least one
other ALK
inhibitor for
metastatic disease or
whose disease...
-
treatment of
adults with ALK‑positive
advanced NSCLC previously treated with
crizotinib. In the
United States, it is
indicated for the
treatment of
people with...
-
include velpatasvir/sofosbuvir, sofosbuvir/daclatasvir, osimertinib,
crizotinib, daclatasvir, sofosbuvir, afatinib, axitinib, brigatinib, baricitinib...
- been increasing. In 2016, the
small molecule tyrosine kinase inhibitor,
crizotinib, was
approved for the
treatment of
patients with
metastatic NSCLC whose...
-
responses to
crizotinib while 1
patient previously treated with a corticosteroid, prednisone,
continued to have
progressive disease on
crizotinib; and 3) 6...
-
monotherapy and in
combination with
other agents, such as
binimetinib and
crizotinib. Cao L, Chen S, Sun R,
Ashby CR, Wei L,
Huang Z, et al. (2023). "Darovasertib...
- patients.
Crizotinib,
which gained FDA
approval in
August 2011, is an
inhibitor of
several kinases,
specifically ALK, ROS1, and MET.
Crizotinib has been...
